Suche

Early diagnosis by testing in an early stage of disease and early intervention by effective drugs might alter the course of the disease especially in the population most at risk for severe course of disease. In a population-based approach, altering the course of disease in this population most…

Chloroquine is perhaps one of the most prescribed drugs in the world and in the past Europeans visiting malaria-endemic areas for decades received chloroquine prophylaxis and continued it for 2 months after their return. The recommended weight-adapted dose of hydroxychloroquine (sulfate) for…

The current outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is a global health emergency with a case fatality rate so far approximately 4% and a growing number of confirmed cases (>57.000) in Germany. There is no data available…

Ziel ist die Durchführung einer klinischen Phase-I-Studie, in der zwei vordefinierte Peptidcocktails (Arm 1: HLA-Klasse II/ Arm 2: HLA-Klasse I) in Kombination mit dem TLR1/2 Agonisten XS15 in Montanide bei Patienten ≥ 75 Jahre mit einem hohen Risiko für schwere Verläufe der COVID-19 Erkrankung…

Ziel ist die Durchführung einer klinischen Phase-I-Studie, in der eine therapeutische Vakzinierung mit zwei vordefinierten Peptidcocktails (Arm 1: HLA-Klasse II/ Arm 2: HLA-Klasse I) in Kombination mit dem TLR1/2-Agonisten XS15 in Montanide bei Patienten ≥ 65 Jahre mit nachgewiesener SARS-CoV-2…

Antibody binding sequences are generated using an antibody phage library at the Department of Biotechnology, Technische Universität Braunschweig. These sequences are tested for binding to the receptor binding domain of the viral spike protein and for virus neutralizing capacity in vitro. A lead…

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.

Randomisierte Phase 3 Studie zur Sicherheit und antiviralen Wirksamkeit von Remdesivir bei schwerem Covid-19-Verlauf. Verglichen werden zwei Remdesivir Regime bezüglich des klinischen Verlaufes innerhalb von 14 Tagen.

The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.